The End of the Shortage Is Not the End of the Compounding Question

For independent clinics, a drug's availability is only one part of the compounding question. The Food and Drug Administration's April update draws a sharper line around what happens when a commercially available drug is no longer in shortage: a compounded product does not become broadly interchangeable with an approved one simply because a practice can order it.

The agency says section 503A generally requires compounding for an identified patient on receipt of a prescription, and restricts the regular or inordinate compounding of products that are essentially copies of commercially available drugs. Its discussion also leaves room for a documented prescriber determination that a change makes a significant difference for an individual patient. That is an individual-patient exception, not a blanket business model.

The 503B pathway has different rules for bulk substances. Treating 503A and 503B as a single category can obscure the question that matters: which entity made the product, under which provision, and on what basis? For clinic operators, the practical work is less about a sweeping headline than a record that connects a particular order to a particular patient's need. The FDA's page lays out the agency's position; it does not adjudicate every clinic's circumstances.